The growth in demand for cosmetic, graft and organ transplant surgical procedures, the increased use of antineoplastic and immunosuppressive agents, as well as multidrug resistance are some of the factors responsible for the marked rise in fungal infection rates in recent years. Consequently, there have been renewed calls from both the public and private sectors for new and improved drug targets to replace existing antifungal therapies, many of which have been in clinical circulation for several decades. Plants select themselves in such endeavors owing to their superior numbers and vast chemical diversities. With this as a backdrop, this survey examines the antifungal activities of Amaryllidaceae plant extracts against various fungal pathogens. Good growth inhibitory activities (MICs <1 mg/mL) reported in several instances are noteworthy and could guide efforts targeting the active antifungal principles.
In spite of the advances made in human medicine and nutrition over the past several decades, infectious diseases remain a formidable challenge to public health [1a] . This is particularly true for developing nations where progress is often hampered by ailing healthcare infrastructure, limited access to the attendant medical facilities as well as a shortage of essential medicines [1b] . The overall situation has not been aided by the loss of efficacies of existing drugs, the adverse effects of long-term therapies as well as the widespread emergence of multidrug resistance [1a] . The antifungal drug era since its inception has been dominated by microorganism derived chemical entities such as amphotericin B and nystatin whose impact on human health and well-being has been immense [1c] . Although these still remain sturdy in the clinical setup, synthetic antifungals such as fluconazole and ketoconazole have in recent decades emerged as likely successors [1d] . The increase in occurrence of invasive fungal infections is seen to be coincident with an increase in the immuno-compromised patient population, such as organ transplant recipients as well as cancer and HIV sufferers [1e,f]. In attempts to minimize the threats posed by multidrug resistance, there have been fervent calls to broaden the chemical basis of antifungal drug discovery [1a] . Furthermore, repurposing strategies are being actively pursued in laboratories across the globe with the express purpose of finding new activities for old drugs [2a] . With their exceptional numerical representation as well as their vast chemical diversities, plants are strategically positioned as an automatic choice in such endeavors [2b]. Coupled to these properties is the widespread and evidencebased usage of plants and plant products in traditional systems of remediation of fungal diseases [1a,2c,d] .
The bulbous plant family Amaryllidaceae is recognizable for its floral resplendence as epitomized by the daffodils (Narcissus pseudonarciccus) [3a] . Equally appealing are its alkaloid constituents, a chemotypic feature not discernible outside the family [3b]. These belong almost exclusively to the isoquinoline alkaloid group of secondary metabolites [3b]. Many of these constituents are attractive from a biological standpoint due to their interesting and diverse activities in a wide range of assays [3c]. This has led to breakthrough discoveries in the cancer and motor neuron disease arenas, which have to a considerable extent been guided by traditional medicinal approaches towards these diseases [3d,e]. Similarly, there is a significant representation of the Amaryllidaceae in traditional systems of medicine pertaining to infectious diseases [3f]. As many as fifty species of the family are identifiable with such distinct functions in ethnic medicine [3f]. This survey focuses on the fungal aspect of infectious diseases pertaining to Amaryllidaceae plant extracts and their activities against an array of fungal pathogens. Also considered are instances where the plants examined are of relevance to traditional medicine.
In spite of the pharmaceutical appeal of the Amaryllidaceae in the cancer and motor neuron disease areas [3d,e], a significant amount of work has been carried out to ascertain its antifungal properties. To date extracts of twenty-four species representing twelve genera have been examined against around twenty fungal pathogens (Table  1) . Crinum and Narcissus were the genera most studied with four and five of their species, respectively, having been exposed to various fungal pathogens. Of the pathogens studied, Aspergillus (three species) and Candida (eight species) were the most represented. In their seminal study, Ieven et al. (1979) recorded the first data on the antifungal activity of Amaryllidaceae plant extracts, including the two Clivia species C. cyrtanthifolia and C. miniata [4] . In the event, both plants were inactive in cultures of Aspergillus flavus, Aspergillus fumigatus and Aspergillus niger, but responded positively to Candida albicans, Microsporum canis, Trichophyton mentagrophytes and Trichophyton rubrum [4] . The Crinum species have only been tested against the Candida pathogens C. albicans, C. glabrata, C. krusei, C. lusitaniae and C. tropicalis, where they were either inactive or exhibited low activities [5] [6] [7] [8] . Of the fungal growth inhibitions observed, water and MeOH leaf extracts of C. asiaticum both showed MICs of 25 mg/mL against C. albicans [7] . In parallel with the type culture screen, all six extracts were also screened against two clinically procured isolates of C. albicans wherein the DCM extract was as much as four times more active (MIC 12.5 mg/mL) compared to the commercial strain [7] . This study also demonstrated the lack of activity of any of the leaf extracts against either C. lusitaniae or C. tropicalis [7] . By the same token, acetone and DCM extracts reflected MICs of 25 mg/mL in the examination of a clinical isolate of C. krusei [7] . 7 9 7 10 7 12 7 10 7 9 7 9 7 10 7
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Apart from this, MeOH extracts of C. augustum and C. jagus inhibited the growth of C. albicans, with the former (IC 50 78 g/mL) shown to be more active than the latter (inhibition zone diameter of 14 mm at 100 mg/mL) [6, 8] . The two Cyrtanthus species C. contractus and C. obliquus were only exposed to C. albicans cultures where both were shown to be active with MIC values for various bulb extracts ranging from 0.195 to >25 mg/mL [9] [10] [11] . Of these two species, C. obliquus is documented in South African TM [9, 10] .
Haemanthus albiflos, herein the sole representative of the genus Haemanthus, was amongst twenty-four endemic South African plants from various families examined for anti-candidiasis activity [12] . These plants were selected in the screen against the fungal pathogen Candida albicans based on their reputed use medicinally for various infections [12] . South Africa is widely held as the epicentre of the global HIV-AIDS epidemic, where HIV prevalence hovers around the 20% mark [13] . In addition to the diverse factors identified in the progression of the disease, as high as 50-80% of AIDS patients will contract a fungal infection at some point of its course [1d] . There is also a marked proliferation of AIDS in rural South Africa where there is often limited access to mainstream medical resources [12] . Nonetheless, such areas often benefit from a close association with ethnic medicine so that the pursuit of alternative or complementary therapies in this clinical environment becomes more amenable [12] . With this in mind, Motsei et al. (2003) set out to identify those plants which were active enough to be implemented as treatments for candidiasis in AIDS patients at rural community clinics around South Africa [12] . Although aqueous extracts of two plants (Allium sativum and Polygala myrtifolia) exhibited good activities against Candida albicans (MICs 6.25 mg/mL, respectively), the responses from the remaining plants including Haemanthus albiflos, were disappointing (MICs >25 mg/mL in most instances) (Table 1 ) [12] . In relation to the EtOH, EtOAc and Hex extracts examined, the lowest activity (MIC 2.09 mg/mL) was detected for several plants, but the activities for Haemanthus albiflos were again poor in these circumstances (MICs 8.35 or >8.35 mg/mL) [12] . Similarly, aqueous and organic extracts of both bulbs and leaves of Haemanthus albiflos subjected to two clinical isolates of Candida albicans (from an adult and a fivemonth old patient) proved to be mostly disappointing (MICs 8.35, >8.35 or >25 mg/mL) [12] . However, activities for the EtOH and EtOAc leaf extracts in the isolate taken from the child were encouraging (MICs 2.09 mg/mL, respectively) [12] . In spite of this, Tulbaghia violacea with the lowest MIC value of 0.13 mg/mL for its bulb EtOAc extract in the second clinical isolate was deemed as most likely to succeed on the clinic floor [12] .
The four Turkish medicinal plants Galanthus elwesii, Leucojum aestivum, Narcissus tazetta and Pancratium maritimum were all inactive against the plant pathogenic fungus Cladosporium cucumerinum [14] . Of these, only P. maritimum exhibited no activity against C. albicans [14] , the remaining three having MICs of 1.024, 0.256 and 0.256 mg/mL, respectively [15] . Whole plant water extracts of N. tazetta and N. pseudonarcissus at 50-500 g/mL were both shown to be inactive against the three Aspergillus species (Table 1) , but active against Microsporum canis, Trichophyton mentagrophytes and Trichophyton rubrum [4] . The other three Narcissus species, including N. bulbocodium, N. jonquilla and N. poeticus exhibited promising activities against C. albicans with MIC values of 1.024, 0.128 and 0.256 mg/mL, respectively [15] . All four Narcissus species studied by Ločárek et al. (2015) also exhibited fungicidal activities towards C. albicans as shown by their MFC values which ranged from 0.256 to 1.024 mg/mL [15] . These authors also examined the effects of the six Amaryllidaceae plants in two clinical isolates of C. albicans, where only N. bulbocodium and Galanthus elwesii were inactive [15] . Clinical isolates of C. dubliniensis, C. glabrata and Lodderomyces elongisporus were also examined and shown to be susceptible to treatments with the six Amaryllidaceae plants, with Leucojum aestivum, N. jonquilla and N. poeticus seen to be particularly effective (MICs of 0.128 mg/mL, respectively) [15] .
The Latin American representative Hymenocallis littoralis was active in four of the seven fungal culture systems screened [4, 16] , although the only numerical data available is that of its leaf extract against C. albicans (MIC 6.25 mg/mL) [16] . Results for the Chinese medicinal plant Lycoris chinensis were discouraging as its extracts were inactive against Aspergillus niger, Candida albicans and Trichophyton rubrum [17] . The popular Afro-Eurasian representative Pancratium maritimum was the most studied plant with its extracts having been exposed to ten different fungal pathogens, including six Candida species [14, 18, 19] . Good inhibitory activities were seen against Aspergillus fumigatus (MIC 0.49 mg/mL) and Trichophyton mentagrophytes (MIC 0.98 mg/mL), but the best activity was observed in cultures of Rhizopus microsporus (MIC 0.06 mg/mL) following treatment with an ethanolic flower extract [19] . Not shown in Table 1 are activities against the three Candida species C. guillermondii, C. krusei and C. pseudotropicalis for which inhibition zone diameters measured were 26, 20 and 11 mm, respectively, when MeOH bulb extracts were applied at 60 g/disc [18] . The other Pancratium specie (P. illyricum) has only been investigated against Candida albicans wherein methanolic bulb and leaf extracts exhibited IC 50 values of 39 and 78 g/mL, which were nevertheless mild in comparison to the reference drug amphotericin B (IC 50 0.039-0.625 g/mL) [20] .
The remaining Afro-Eurasian genus Sternbergia afforded two species (S. lutea and S. sicula) which were studied against the single pathogen C. albicans [21] . In the disc diffusion assay, organic and aqueous extracts of bulbs and aerial parts of the plant applied at 20 g/disc exhibited zone inhibition diameters ranging from 8-12 mm [21] . The broadest zone (12 mm) was observed for the aqueous bulb extract of S. lutea, comparable to the 17 mm zone observed for the antifungal standard nystatin [21] . The African genus Scadoxus had two representatives (S. pseudocaulus and S. puniceus), both of which were examined against C. albicans and Cryptococcus neoformans [10, 22, 23] . In these cases, aqueous and organic extracts of bulbs, leaves and whole plants exhibited MICs in the range 0.512 to 12.5 mg/mL against C. albicans [10, 22, 23] , with the whole plant MeOH extract of S. pseudocaulus exhibiting the best activity [23] . These two cases also represent the first time that any Amaryllidaceae plant has been exposed to Cryptococcus neoformans cultures, wherein S. pseudocaulus (MIC 1.024 mg/mL) performed better than S. puniceus (MIC 10.7 mg/mL) [22, 23] . Furthermore, the Cameroonian medicinal plant S. pseudocaulus was also active against Candida parapsilosis, but with a MIC (1.024 mg/mL) half that seen for C. albicans [23] . The study by Pagning et al. (2016) also involved the partitioning of the original MeOH extract of S. pseudocaulus between several solvents to give fractions ranging from non-polar (hexane) to polar (water) which were subsequently also exposed to the C. albicans, C. parapsilosis and Cryptococcus neoformans cultures [23] . In these instances the MIC values ranged from 0.128 to >2.05 mg/mL, with the EtOAc fraction shown to have the best activity in both Candida cultures [23] .
In conclusion, although fungal infections are often, and sometimes inadvisedly, considered as less threatening than those caused by other microbial pathogens, they are becoming increasingly prevalent and more invasive in the clinical setup. The calls to supplant existing antifungal schedules have become mundane in some quarters, but have not gone unheeded in others. Plants have been earmarked as a viable platform for antifungal drug discovery with a foundation reinforced by numerical representation and chemical diversity. In this context, studies on the antifungal properties of Amaryllidaceae plant extracts are significant. Furthermore, the space to explore in this area is wide open as the twenty-four species described herein are a small fraction of the over one thousand species known in the family. Microgram per millilitre activities seen in some instances are encouraging and should serve as a catalyst in ongoing attempts to identify the active constituents.
